The company has been the quite achiever, this company now has around $5m cash in its coffers, has started a phase 1/11 human trial and has multiple opportunities for their unique strains-- which are showing significant anti inflammatory characteristics. The results of these trials will hopefully bring everyone's attention to us, and a re rate.
What they haven't been good at , is highlighting and convincing the market of what I believe is their significant potential-- at $40m M/C I believe they are just cheap and continue to add to my holdings. Which other company doing human trials is capitalised at under $100 to $150m-- I can't find one.
Cheers
The company has been the quite achiever, this company now has...
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.58M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 86 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.2¢ | 6584 | 3 |
View Market Depth
| Last trade - 16.12pm 03/05/2024 (20 minute delay) ? |
| NTI (ASX) Chart |
Day chart unavailable